Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH) (opens ClinicalTrials.gov)
- Sponsor
- Ohio State University
- Enrolment
- 23,280,000
- Started
- 2025-09-15
- Last update
- 2025-09-23
Conditions: Cardiovascular Kidney Metabolic Syndrome
Interventions: Intervention, Active Comparator